• 대한임상독성학회지
• /
• 제10권2호
• /
• pp.111-117
• /
• 2012

Purpose: In Korea, few studies have examined the acute toxicity of anti-obesity drugs. The purpose of this study is to analyze the general characteristics and clinical aspect of acute anti-obesity drug intoxication. Methods: We retrospectively investigated patients admitted to the emergency department after anti-obesity drug intoxication between March, 2004 and February, 2012. The medical records of these patients were reviewed for demographic data, toxicologic history, time elapsed to presentation, clinical symptoms and signs, treatment, and outcome. Results: There were a total of 18 anti-obesity intoxication cases during the study period; of 16 which were included in our study. The purchasing route of the anti-obesity drug was mainly through a doctor's prescription (68.8%), however, some were obtained through the internet and the pharmacies. The mean time to The most commonly ingested antiobesity drug was sibutramine (31.3%) and many of the cases (62.5%) were multi-drug ingestions. The most common clinical manifestations were gastrointestinal symptoms (94%), but, CNS symptoms (75%) and cardiovascular symptoms (75%) were almost equally present. 13 patients (81%) were discharged after clearance of toxic symptoms and signs with a mean observational period of 7.0 hours. 3 patients were admitted for observation and treatment; of which 1 patient died due to fatal complications. Conclusion: Most anti-obesity intoxications show mild toxicity and a nonfatal clinical course. However, the recent trend toward prescribing psychostimulant anti-obesity medication, which can be fatal after an acute overdose, calls physicians' attention to treating of anti-obesity intoxications.

• The Korean Journal of Medicine
• /
• 제93권6호
• /
• pp.501-508
• /
• 2018

Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.

• 비만대사연구학술지
• /
• 제1권1호
• /
• pp.43-45
• /
• 2022

Intensive lifestyle modifications and anti-obesity medications are essential for obesity treatment. Antiobesity medications should be selected according to the patient's comorbidities, symptoms, and preferences. This case report describes the treatment of a morbidly obese patient with a history of depression, who complained of tingling and numbness after total thyroidectomy for papillary thyroid cancer. Very low-dose controlled-release phentermine/topiramate was prescribed and intensive lifestyle modifications were encouraged. As a result, the patient effectively lost weight and reached a near-normal weight without adverse drug effects. This implies that even an off-label anti-obesity medication low dose may be better for some patients, and the most important factor in obesity treatment is patient-tailored treatment.

• 대한의생명과학회지
• /
• 제11권2호
• /
• pp.89-101
• /
• 2005

Obesity is increasing worldwide and has become a major health burden in Western societies affecting every third American and every fifth European. Obesity makes a major contribution to morbidity and mortality, predisposing individuals to cardiovascular disease and diabetes. Many new substances are currently being investigated for their usefulness in the pharmacotherapy of obesity. Most anti-obesity drugs can be divided into four groups: those that reduce food intake; those that alter metabolism; those that increase thermogenesis; and those that regulate hormone involved in feeding behavior. In this article we review these and other agents available in various countries for the treatment of obesity. Perhaps more importantly, we have focussed on areas of potential productivity in the future. Over the last 5 or so years, this impetus in obesity research has provided us with exciting new drugs targets involved in the regulation of feeding behavior and cellular mechanism involved in energy expenditure. Recent development in the quest for control of human obesity include the discovery of hormones, neuropeptides, receptors and transcription factors involved in feeding behavior, metabolic rate and adipocyte development. For developing new, perhaps even more specific pharmacological agents, further research is needed to understand the individual different genetic and physiological basis of obesity. It remains the hope of research scientists that in the not too distant future we shall see a new class of anti-obesity drugs arising logically from the molecular biology revolutions.

• 비만대사연구학술지
• /
• 제1권2호
• /
• pp.83-88
• /
• 2022

Obesity increases the risk of developing metabolic diseases such as hypertension, type 2 diabetes, hyperlipidemia, and cardiovascular diseases, as well as some cancers. To prevent the occurrence of these diseases and death, it is essential to manage obesity. Though there are several treatments for obesity, lifestyle interventions, such as diet and exercise, and drug therapy are most widely used in clinical practice. Among the anti-obesity drugs available, the weight loss effect of naltrexone/bupropion has been well-proven. We present a case study in which naltrexone/bupropion, a glucagon-like peptide-1 agonist, and a sodium-glucose transporter 2 inhibitor showed significant weight loss and improved metabolic parameters. Additionally, the management of type 2 diabetes and hypertension, which are common diseases in patients with obesity, was also included.

• 한국식품과학회지
• /
• 제48권5호
• /
• pp.424-429
• /
• 2016

비만은 전세계적으로 심각한 문제로 인식되고 있다. 최근 체중감소와 유지를 위한 다이어트제품에 비만치료제와 그 유사물질, 사용금지 성분들이 발견되고 있다. 정부의 감시를 피하기 위하여, 비만치료제의 화학구조를 일부 변형시킨 유사물질이 지속적으로 합성되고 있다. 부정물질이 혼입된 다이어트식품을 신속하게 검사하기 위하여, 국내에서 판매되는 제품과 해외 인터넷 사이트에서 128건의 다이어트제품을 구매하였으며, HPLC-PDA와 LC-MS/MS로 21종의 부정물질을 동시분석하였다. 시험법의 유효성 검증은 선택성, 직선성, 검출한계, 정량한계, 정확성, 정밀성을 검토하였다. 분석결과 31건의 시료에서 부정물질이 검출되었으며, 검출수준은 시부트라민 9.9-135.3 mg/g, 요힘빈 0.2-17.5 mg/g, 이카린 1.8 mg/g이었다. 본 연구의 부정물질 분석법은 간단하면서도 신속한 분석법으로, 식품안전관리를 위한 기초자료로 활용될 수 있을 것으로 사료된다.

• 정신신체의학
• /
• 제29권2호
• /
• pp.86-94
• /
• 2021

연구목적 항정신병약물 사용시 체중 증가 위험이 높고, 정신질환자의 비만 유병률도 높다. 비만은 다양한 합병증을 유발하고 치료 순응도와 삶의 질을 저하시키기 때문에 정신질환자의 비만 관리는 중요하다. 방 법 본 종설에서는 학술 검색을 통하여 항정신병약물 사용시 발생할 수 있는 비만의 관리 전략에 대해 정리해 보았다. 결 과 치료 초기부터 비만관련 위험 요인과 관련 지표(체중, 체질량지수, 허리둘레,공복혈당 및 공복지질, 혈압)에 대해 평가하고, 정기적인 모니터링을 시행한다. 항정신병약물을 사용하며 비만이 유발된 경우 대사성 위험이 적은 약제로 변경을 시도할 수 있다. 환자 및 가족에서 비만 관리 필요성과 식이 및 운동 조절 등에 대한 충분한 안내도 필요하다. 비약물적 치료를 통해 적절한 체중 감량이 이뤄지지 않는 경우 항비만약물들의 사용도 고려할 수 있다. 결 론 항정신병약물 사용시 유발되는 체중 증가와 비만 관리를 위하여 비약물적, 약물적 요법을 적용할 수 있다. 항비만약물을 사용할 경우에는 정신질환의 특성, 약물의 안정성, 약물 상호작용을 고려해야 한다.

• 한국응용과학기술학회지
• /
• 제35권2호
• /
• pp.492-501
• /
• 2018

Obesity is a worldwide disease and one of the major risk factors. Virus among many factors can lead to obesity. Adenovirus 36 (Ad-36) is the adipogenic virus linked with human obesity. Nevertheless, there is no drug to treat both Ad-36 infection and obesity associated with virus. For the precedent study on anti-cholesterol test, Distylium racemosum (D. racemosum), Quercus salicina (Q. salicina) and Raphiolepis indica (R. indica) were selected. This study was carried out to evaluate the anti-cholesterol effects, anti-lipid effects and inhibition of Ad-36 replication from three extracts. D. racemosum ($50{\mu}g/mL$) inhibited lipid accumulation on 3T3-L1 adipocyte. D. racemosum inhibited adipocyte differentiation through suppression of regulator peroxisome proliferator-activated receptor-${\gamma}$ ($PPAR{\gamma}$) genes and adipocyte-specific genes such as adipocyte protein 2 (aP2). D. racemosum inhibited replication of Ad-36 at $50{\mu}g/mL$ of concentration. Therefore, the extract of D. racemosum could be a candidate for development of anti-Ad-36 and anti-obesity drugs.

• 한국식품위생안전성학회지
• /
• 제25권1호
• /
• pp.30-35
• /
• 2010

식품 중 비만치료제 시부트라민의 유사물질인 데스메틸시부트라민을 규명하였다. 데스메틸시부트라민 함유 시료로부터 메탄올을 이용하여 대상성분을 추출하고 핵산으로 세척 등을 통하여 정제한 후 HPLC/PDA, HPLC/MS, HPLC/MSIMS 및 NMR로 확인 및 분석하였다. 또한, 식품 중 시부트라민 및 데스메틸시부라민을 분석하기 위하여 균질화한 시료를 디클로로메탄으로 추출하여 여과, 농축하고 메탄올로 희석하여 HPLC/UV로 분석하였다. 평균 회수 87~91%이었으며, 정량한계는 $2.5\;{\mu}g/kg$이었다. 분석 결과 식품시료 54건에서 시부트라민 및 데스메틸시부트라민이 검출되지는 않았다.

• 한방재활의학과학회지
• /
• 제30권4호
• /
• pp.41-53
• /
• 2020

Objectives The purpose of this study was to investigate the effects of Silbi-san on the antioxidant and fat accumulation inhibition and to analyze the anti-obesity effect by analyzing the changes in serum lipid composition in obese mice. Methods We compared contents of phytochemicals like total polyphenols and total flavonoid and antioxidant activities such as 2,2-dipheny-1-picrylhydrazyl and 2.2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) radical scavenging activity. After Silbi-san in 3T3-L1 cells in vitro and mouse adipose tissue ex vivo, we quantified intracellular triglyceride accumulation and lipolysis. Moreover, the anti-obesity activity though inhibiting pancreatic lipase were analyzed. In 3T3-L1 cells, morphological changes showed that control cells had many lipid while cells treated with Silbi-san had less lipid accumulation. 30% EtOH Silbi-san treatment also suppressed the fat absorption by inhibiting the activity of pancreatic lipase and led to high lipolysis through promoting glycerol release. The experimental group was divided into four groups: Normal group fed normal feed, Control group fed 60% high fat diet (HFD) and distilled water, drug group fed 60% high fat diet and 200 mg/kg of Silbi-san water extract, drug group fed 60% HFD and 200 mg/kg of Silbi-san 30% ethanol extract. Results Serum total cholesterol content and serum low density lipoprotein-cholesterol content were significantly decreased in the Silbi-san extract group compared to the control group, serum high density lipoprotein-cholesterol content was significantly increased in Silbi-san extract group. Conclusions In this study, the antioxidant and fat accumulation inhibitory effects of Silbi-san were confirmed.